Arrowhead Announces the Agenda for its 2nd Annual Drug Delivery Summit in San Francisco, California on May 1st and 2nd, 2008

Share Article

Arrowhead Conferences has announced the agenda for its 2nd Annual Drug Delivery Summit: New Technologies and Commercialization Trends in San Francisco, California on May 1st and 2nd, 2008.

Arrowhead Conferences has announced the agenda for its upcoming 2nd Annual Drug Delivery Summit, set to take place in San Francisco, CA on May 1st and 2nd, 2008. The field of drug delivery continues to have an immense impact on the pharmaceutical and biotech industries in 2008. Companies both big and small depend on drug delivery technologies at numerous stages in a product's lifecycle. Drug delivery has become more than just a tool to extend patents, but has become an integral component of the clinical drug development process.

Arrowhead's 2nd Annual Drug Delivery Summit has been organized to examine drug delivery technologies and systems from both a commercial and scientific standpoint. Leaders from the drug delivery and pharmaceutical industry will discuss the latest innovations and technologies coming out of the industry as well as various issues relating to commercialization of therapies utilizing novel drug delivery technologies.

Key themes of this conference will include:

  •      An examination of key emerging technologies in the following areas:

     - injectable
     - ultrasonic
     - electroporation
     - inhalable
     - transdermal
     - transmucosal
     - nanotechnology
     - controlled release
     - RNAi delivery
     - and other modes of drug delivery

  •      Keys to the formation of successful alliances
  •      Unlocking the door to delivery of macromolecules
  •      Mapping of bioavailability as a key to successful formulation
  •      Overcoming first pass metabolism and absorption window problems
  •      Patent and IP protection in drug delivery
  •      Considerations and best practices in contract manufacturer-drug delivery partnerships
  •      Trends in tumor and organ targeting
  •      Making the deal - structuring mutually beneficial licensing arrangements

Presentations to be Heard Include:

  • Drug Delivery and Specialty Pharma IPO vs. M&A Decision Making: What Investors vs. Strategic Acquirors are Looking For
  • Collaboration and Licensing as an Approach to Solving Drug Delivery Problems
  • Waiting to Inhale: The Prospects for Inhaled Delivery Technologies
  • Keys to a Successful and Profitable Contract Manufacturing Partnership
  • Novel Injectable Delivery Systems for Biologicals
  • Understanding Regional Bioavailability as a Driver for Realising the Success and Value from Modified Release Oral Formulations
  • Intracellular Drug Delivery Mediated by High Intensity Focused Ultrasound (HIFU)
  • Electroporation as a Clinical Stage Technology for Intracellular Delivery of Nucleic Acids
  • Protecting Intellectual Property in the Changing Patent Landscape
  • The Staccato System: Inhaled Drug Delivery for Rapid Relief of Acute Systemic Medical Conditions
  • Molecular Imaging and Drug Delivery
  • Key Factors in Ensuring Early Commercial Success in Specialty Pharma: Planning to "Go it Alone"
  • Transdermal Delivery: Reaching Beyond the Stratum Corneum Through RF MicroChannels
  • Prefilled Products, Platforms for Today and the Future
  • Delayed Pulse Delivery as a Method to Overcome First Pass Effects

Speakers at this event include:

Philip G. Green, Ph.D., Director Alternative Delivery Systems, BD-Medical Pharmaceutical Systems
Shawn Cross, Managing Director, Thomas Weisel Partners
Tatyana Naranda, Director Business Development, Alexza Pharmaceuticals
Dr. Ron Forster, Director Drug Product & Device Development, Amgen
Walter Gacek, Director Business Development, Accellent
Yael Weiss, MD, Ph.D, Director Licensing and External Research, Merck & Co.
Allen Downs, Sr Executive Director Licensing & Business Development, Purdue Pharmaceuticals
Mark Bunger, Research Director, Lux Research
Dr. Claire Evans, Director Protein Therapeutics, Ichor Medical Systems
Meghan Fitzgerald, Chief Business Officer, Vion Pharmaceuticals
Dr. Peter Scholes, VP Pharmaceutical Sciences, Pharmaceutical Profiles Ltd.
Ed Cannon, Ph.D, CEO, Aerovectrx
Dr. Verne Cowles, Sr. Director of Preclinical Studies, Depomed
Andrew Forman, Sr Analyst & Managing Director, WR Hambrecht
Judith Kornfeld, Vice President of Business Development, TransPharma Medical

Please visit our website at to view the complete agenda and list of speakers.

Who should attend:

Individuals from the following industries:

  •      Drug delivery companies
  •      Pharmaceutical companies
  •      Biotechnology companies
  •      Specialty pharmaceutical companies
  •      Medical device manufacturers
  •      Investment and capital markets community

Individuals from the following areas/departments will greatly benefit from attending:

  •      Business development
  •      Executive management
  •      Corporate development
  •      Technology assessment
  •      Commercial development
  •      New product planning
  •      Drug delivery scientists
  •      Pharmaceutical science
  •      Licensing
  •      Intellectual property
  •      Outsourcing
  •      Strategic planning & development
  •      Scientific / technology development
  •      Marketing
  •      R&D

as well as individuals from

  •      Investment banks and venture capitalist firms
  •      Academic institutions
  •      Consultancies

For more information about this conference, please visit or contact us at 312-244-3703 or arrowheadconferences @

To enquire about sponsorship and/or exhibiting at this conference please contact marketing @


Share article on social media or email:

View article via:

Pdf Print